Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older

Rahkonen, Terhi; Eloniemi‐Sulkava, Ulla; Rissanen, Saara M.; Vatanen, Anu; Viramo, Petteri; Sulkava, Raimo

doi:10.1136/jnnp.74.6.720

Cited by 190 publications

(132 citation statements)

References 30 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…In a large Finnish community study in a general population aged 75 years and older, the prevalence of DLB was 5%, comprising 22% of all demented subjects [66]. In the recent population-based Vantaa 85+ study, Lewy-related pathology was seen in 36% of 304 subjects (mean age: 92.5 years) and categorized as follows: 3% brainstem predominant, 14% limbic, 15% diffuse neocortical type (4% nonclassifiable) [41].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders

Jellinger¹,

Attems

2011

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background: While the prevalence of Alzheimer disease (AD) increases with age, little is known about the frequency of dementia with Lewy bodies (DLB) in the oldest old. A retrospective hospital-based study compared the relative prevalence of DLB among very old individuals. Methods: 1,100 consecutive autopsy cases of demented patients aged over 70 years (mean age: 83.9 ± 5.4 years) were examined using standardized neuropathological methods and current diagnostic consensus criteria. Results: Evaluation of three age groups (8th–10th decade) showed a significant increase in the relative prevalence of AD with cerebrovascular lesions including mixed dementia, while AD with Lewy body (LB) pathology showed a mild but insignificant age-related increase. Both ‘pure’ AD and vascular dementia showed a mild but insignificant decline, while DLB (without severe AD pathology) decreased progressively. While the severity of Lewy pathology in DLB slightly decreased with age, concomitant Alzheimer-like pathology increased progressively. Conclusion: Whether DLB in the oldest old represents a distinct group is a matter of discussion, but the relative prevalence of AD with LB in our sample remained fairly stable.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders

Jellinger¹,

Attems

2011

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…François and colleagues used data from a Finnish epidemiological study (the Kuopio 75+ Study 143 ) to classify patients at the start of the model. In the UK study by Jones and colleagues, the initial distribution of patients by severity, dependency and institutionalisation was based on a UK epidemiological study -the LASER AD Study 146 [see the section 'Costing considerations in the treatment of AD' (p. 108) for an outline summary 72 and data from the LASER-AD Study.…”

Section: François and Colleagues'/jones And Colleagues' Model Of Ad Pmentioning

confidence: 99%

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

164

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key ...

show abstract

“…Dementia with Lewy bodies (DLB) is widely regarded as the third most common type of dementia, although reliable epidemiological data is sparse [2,3]. There is a considerable overlap between DLB and Parkinson's disease dementia (PDD) [4].…”

Section: Introductionmentioning

confidence: 99%

Differences in Drug Therapy between Dementia Disorders in the Swedish Dementia Registry: A Nationwide Study of over 7,000 Patients

Johnell

Religa

Eriksdotter

2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: We aimed to study whether there are differences between dementia disorders and the use of anti-dementia drugs and antipsychotics (neuroleptics) in a large population of dementia patients. Methods: Information about dementia disorders was obtained from the national Swedish Dementia Registry (SveDem) 2007-2010 (n = 7,570). Multivariate logistic regression analysis was performed to investigate the association between dementia disorders and the use of anti-dementia drugs and antipsychotics, after adjustment for age, sex, residential setting, living alone, MMSE score and number of other drugs (a proxy for overall co-morbidity). Results: More than 80% of the Alzheimer's disease (AD) and 86% of dementia with Lewy bodies (DLB) patients used anti-dementia drugs. Women were more likely than men to be treated with cholinesterase inhibitors. A higher MMSE score was positively associated with the use of cholinesterase inhibitors, but negatively associated with NMDA receptor antagonists and antipsychotics. Use of antipsychotics was 6% overall; however, it was 16% in DLB patients with an adjusted odds ratio of 4.2 compared to AD patients. Conclusion: Use of anti-dementia drugs in AD was in agreement with Swedish guidelines. However, use of antipsychotics in DLB patients was high, which might be worrying given the susceptibility of DLB patients to antipsychotics.

show abstract

Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older

Cited by 190 publications

References 30 publications

Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders

Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Differences in Drug Therapy between Dementia Disorders in the Swedish Dementia Registry: A Nationwide Study of over 7,000 Patients

Contact Info

Product

Resources

About